Skip to main content
Who LUTATHERA Could Help

LUTATHERA has been shown to help people with NETs in 2 separate clinical trials.

Trial 1: LUTATHERA Was Studied in People Who Had Already Tried Long-Acting Octreotide Alone

This clinical trial studied 229 people with NETs in their midgut. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.

Longer Time Without Disease Progression for Patients Treated With LUTATHERA

People taking LUTATHERA were 79% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone.

79% reduction in risk of the cancer getting worse or death.
More people treated with LUTATHERA had their tumors shrink or disappear compared with people treated with 60 mg of long-acting octreotide alone
13% of people

in the LUTATHERA with 30 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
12% (14 of 116 people)


Complete response (tumors disappear)b:
1% (1 of 116 people)

4% of people

in the 60 mg of long-acting octreotide group

 

Partial response (tumors shrink)a:
4% (4 of 113 people)


Complete response (tumors disappear)b: 

0% (0 of 113 people)

a Tumors shrink by ≥30% from baseline.
b Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.

Trial 2: LUTATHERA Was Studied in People Who Were Newly Diagnosed With GEP-NETs

This clinical trial studied 226 people with NETs in their GI tract, particularly in the pancreas or small intestine. They either received LUTATHERA in combination with 30 mg of long-acting octreotide or 60 mg of long-acting octreotide alone.

Longer Time Without Disease Progression for Patients Treated With LUTATHERA

People taking LUTATHERA were 72% less likely to have their cancer worsen or die compared with people taking 60 mg of long-acting octreotide alone.

72% reduction in risk of the cancer getting worse or death.
More people treated with LUTATHERA had their tumors shrink or disappear compared with people treated with 60 mg of long-acting octreotide alone
43% of people

in the LUTATHERA with 30 mg of long-acting octreotide group

 

Partial response (tumors shrink)c:
38% (57 of 151 people)


Complete response (tumors disappear)d:
5% (8 of 151 people)

9% of people

in the 60 mg of long-acting octreotide group

 

Partial response (tumors shrink)c:
9% (7 of 75 people)


Complete response (tumors disappear)d: 

0% (0 of 75 people)

c Tumors shrink by ≥30% from baseline.
d Tumors disappear and cancerous lymph nodes shrink to <10 mm. The disappearance of any measurable tumors does not necessarily mean that the cancer is completely gone.

GEP-NETs, gastroenteropancreatic neuroendocrine tumors; GI, gastrointestinal; NETs, neuroendocrine tumors.

Important Safety Information

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop...

Approved Use

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE